| Original language | English (US) |
|---|---|
| Pages (from-to) | 1454-1456 |
| Number of pages | 3 |
| Journal | Clinical Microbiology and Infection |
| Volume | 25 |
| Issue number | 12 |
| DOIs |
|
| State | Published - Dec 2019 |
| Externally published | Yes |
Bibliographical note
Funding Information:Outside the current work, P.I.T. reports personal fees as a consultant and membership on the scientific advisory board for MediBeacon Inc.; he also holds equity in the company. P.I.T. and S.B.F. report personal fees as consultants for Takeda Pharmaceuticals, and P.I.T. reports consulting fees for the Bill & Melinda Gates Foundation on infant infections. S.B.F. reports non-financial support from Luminex Corporation, BioMérieux and Copan Diagnostics to support research activities. In addition, PIT has a patent 20190142976 pending to MediBeacon Inc., and is an unpaid consultant to Immunova relating to development of a therapeutic agent for Shiga toxin-producing E. coli. S.B.F. is supported by the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness.
Funding Information:
Outside the current work, P.I.T. reports personal fees as a consultant and membership on the scientific advisory board for MediBeacon Inc. ; he also holds equity in the company. P.I.T. and S.B.F. report personal fees as consultants for Takeda Pharmaceuticals , and P.I.T. reports consulting fees for the Bill & Melinda Gates Foundation on infant infections. S.B.F. reports non-financial support from Luminex Corporation, BioMérieux and Copan Diagnostics to support research activities. In addition, PIT has a patent 20190142976 pending to MediBeacon Inc., and is an unpaid consultant to Immunova relating to development of a therapeutic agent for Shiga toxin-producing E. coli. S.B.F. is supported by the Alberta Children’s Hospital Foundation Professorship in Child Health and Wellness.